Education
About Us
Working with TipRanks
Follow Us
BioMark Diagnostics (TSE:BUX)
:BUX
BUX Stock Chart & Stats
C$0.49
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.49
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.19 - C$0.50
Previous CloseN/A
Volume0.00
Average Volume (3M)16.46K
Market Cap
C$51.49M
Enterprise ValueC$18.64M
Total Cash (Recent Filing)C$2.09M
Total Debt (Recent Filing)C$359.19K
Price to Earnings (P/E)―
Beta-0.23
Next Earnings
Mar 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding105,090,210
10 Day Avg. Volume19,330
30 Day Avg. Volume16,464
Financial Highlights & Ratios
PEG Ratio0.71
Price to Book (P/B)-41.95
Price to Sales (P/S)156.67
P/FCF Ratio-25.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BioMark Diagnostics News
BUX FAQ
What was BioMark Diagnostics’s price range in the past 12 months?
BioMark Diagnostics lowest stock price was C$0.19 and its highest was C$0.50 in the past 12 months.
What is BioMark Diagnostics’s market cap?
BioMark Diagnostics’s market cap is C$51.49M.
When is BioMark Diagnostics’s upcoming earnings report date?
BioMark Diagnostics’s upcoming earnings report date is Mar 03, 2026 which is in 75 days.
How were BioMark Diagnostics’s earnings last quarter?
BioMark Diagnostics released its earnings results on Nov 29, 2025. The company reported -C$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.005.
Is BioMark Diagnostics overvalued?
According to Wall Street analysts BioMark Diagnostics’s price is currently Overvalued.
Does BioMark Diagnostics pay dividends?
BioMark Diagnostics does not currently pay dividends.
What is BioMark Diagnostics’s EPS estimate?
BioMark Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioMark Diagnostics have?
BioMark Diagnostics has 105,090,210 shares outstanding.
What happened to BioMark Diagnostics’s price movement after its last earnings report?
BioMark Diagnostics reported an EPS of -C$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.824%.
Which hedge fund is a major shareholder of BioMark Diagnostics?
Currently, no hedge funds are holding shares in TSE:BUX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioMark Diagnostics
BioMark Diagnostics (BUX) is a biotechnology company focused on the development of innovative diagnostic solutions for early cancer detection. Operating primarily in the healthcare and diagnostics sector, BioMark specializes in creating non-invasive tests that utilize proprietary biomarker technology. Their core products aim to provide accurate and timely identification of various cancers, thereby improving patient outcomes and streamlining the diagnostic process for healthcare providers.
Technical Analysis
Spectral Medical
―
Telo Genomics Corp
―
StageZero Life Sciences Ltd
―
ZYUS Life Sciences
―
Sona Nanotech Inc
―
Options Prices
Currently, No data available
---